Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mixed lipopeptide-based mucosal vaccine candidate induces cross-variant immunity and protects against SARS-CoV-2 infection in hamsters

24 Jan 2025

Abstract excerpt

The global dissemination of SARS-CoV-2 led to a worldwide pandemic in March 2020. Even after the official downgrading of the COVID-19 pandemic, infection with SARS-CoV-2 variants continues. The rapid development and deployment of SARS-CoV-2 vaccines helped to mitigate the pandemic to a great extent. However, the current vaccines are suboptimal; they elicit incomplete and short-lived protection and are ineffective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39849995
DOI: 10.1093/immhor/vlae011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mixed lipopeptide-based mucosal vaccine candidate induces cross-variant immunity and protects against SARS-CoV-2 infection in hamstersPMID 39849995Read ↗

Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human PrimatesSemantic proximity Read ↗

A Multi-Antigen Broad-Spectrum Coronavirus Vaccine Induces Potent and Durable Cross- Protection Against Infection and Disease Caused by Multiple SARS-CoV-2 VariantsSemantic proximity Read ↗

A Single Chimeric Spike Antigen Induces Pan-Sarbecovirus ImmunitySemantic proximity Read ↗

A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster ModelSemantic proximity Read ↗

Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccinesSemantic proximity Read ↗

Challenges and developments in universal vaccine design against SARS-CoV-2 variantsSemantic proximity Read ↗

Sterilizing immunity against SARS-CoV-2 in hamsters conferred by a novel recombinant subunit vaccineSemantic proximity Read ↗

Protection of Hamsters Challenged with SARS-CoV-2 after Two Doses of MVC-COV1901 Vaccine Followed by a Single Intranasal Booster with Nanoemulsion Adjuvanted S-2P VaccineSemantic proximity Read ↗

T cell-mediated protection against lethal SARS-CoV-2 challenge by a synthetic long peptide vaccine targeting conserved CD4+ and CD8+ T cell epitopesSemantic proximity Read ↗

Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1Semantic proximity Read ↗

Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccineSemantic proximity Read ↗

A human-informed multi-patch T-cell vaccine induces broad CD8⁺ immunity and protects against SARS-CoV-2 infectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.